Abstract: In a DC-motor according to the present invention, contact areas of first brushes can be enlarged without enlarging the external diameter of a disk on which a commutator is provided; therefore, the wear resistance of the first brushes can be enhanced while maintaining a good control-response; and at the same time, the axial dimension can be shortened dramatically, so that the DC-motor can be downsized. The first brushes 14 are radially in contact with the commutator 11, and second brushes 15 are axially in contact with slip rings 12 that are formed circumferentially inside the commutator 11.

Abstract: Disclosed herein is a motion vector detection apparatus, including: a spatial luminance difference sum total calculation section; a temporal luminance difference sum total calculation section; a search range calculation section; and a block matching calculation section.

Abstract: A motion vector detection apparatus includes: a base luminance value production section configured to produce a base luminance value of the base block; an effectiveness calculation section configured to calculate an effectiveness degree of each of the pixels of the base block based on luminance values of the pixels of the base block and the base luminance value; a correlation calculation section configured to calculate a correlation degree of the reference block with the base block for each of the reference blocks; a position acquisition section configured to acquire the position of that one of the reference blocks set in the reference frame which exhibits the highest correlation degree with the base block; and a motion vector calculation section configured to calculate a motion vector based on the position of the reference block acquired by the position acquisition section and the position of the base block.

Abstract: [PROBLEMS] To provide a DC motor in which the rattling and the axial deviation of a rotor are restrained without increasing the axial dimension of the motor. [MEANS FOR SOLVING THE PROBLEMS] This DC motor comprises a stator (2) on which coils (4) are provided, a rotor (8) so disposed as to be opposed to the inner periphery of the stator (2) and having magnetic poles, a current-carrying part provided at one end of the rotor (8) and transferring the current fed from a power supply to the coils (4) of the stator (2), a sleeve bearing (6) holding the rotor (8), and a ball bearing (7) holding the rotor (8) and having a load-carrying capacity larger than that of the sleeve bearing (6). The outer ring of the ball bearing (7) is positioned by the stator (2), and the inner ring of the ball bearing (7) is positioned by the rotor (8).

Abstract: A direct current motor includes: a stator (2) on which a plurality of coils (4) is provided; a rotor (8) including a plurality of permanent magnet magnetic poles (9) that is provided so as to face an inner periphery of the stator, and a pipe (11) on one end; a current-carrying portion (19) that is provided on the other end of the rotor (8) and commutates current supplied from a power source to the coils (4) on the stator (2); a sleeve bearing (6) that holds the rotor (8); and a ball bearing (7) that holds the rotor (8) and has a larger load-bearing capacity than that of the sleeve bearing (6). Furthermore, the pipe (11) holds the ball bearing (7) and is in direct contact with the ball bearing (7).

Abstract: In a DC-motor according to the present invention, contact areas of first brushes can be enlarged without enlarging the external diameter of a disk on which a commutator is provided; therefore, the wear resistance of the first brushes can be enhanced while maintaining a good control-response; and at the same time, the axial dimension can be shortened dramatically, so that the DC-motor can be downsized. The first brushes 14 are radially in contact with the commutator 11, and second brushes 15 are axially in contact with slip rings 12 that are formed circumferentially inside the commutator 11.

Abstract: A contrast agent for magnetic resonance imaging which stably circulates in the blood for a long period and which targets solid tumors, with which clear images of cancers may be obtained is disclosed. The contrast agent for magnetic resonance imaging comprises as an effective ingredient a polymeric micelle having gadolinium (Gd) atoms in an inner core and an outer shell including hydrophilic polymer chain segments, which micelle is delivered to a tissue(s) and/or site(s) of solid tumor(s) in vivo, whose micellar structure is dissociated after being accumulated in the tissue(s) and/or site(s).

Abstract: A voltage-controlled crystal oscillator having a voltage-variable capacitive element and a crystal vibrator, includes a control voltage generating circuit, a first charging circuit which charges an output-side capacitive component, a low pass filter having a first resistor and a first fixed capacitor, a timer circuit which outputs a control signal, a first switching element which is turned on in response to the control signal from the timer circuit so as to make both ends of the first resistor open-circuited, a second charging circuit to which a signal synchronized with the control signal is input, and a second fixed capacitor to which an output terminal of the second charging circuit is connected, and which connects a connection point between the first resistor and the first fixed capacitor. The low pass filter is arranged between the voltage-variable capacitive element and a connection point of the control voltage generating circuit and the first charging circuit.

Abstract: Provided are a production process for a polymeric micelle which is stable and has a high drug content and a composition containing such polymeric micelle. Disclosed are a production process for a polymeric micelle, comprising the steps of dissolving a drug and a specific copolymer in a water non-miscible organic solvent to prepare a solution, mixing the resulting solution with water to form an O/W type emulsion and then slowly volatilizing the organic solvent from the solution, and a polymeric micelle composition charged therein with a water-scarcely soluble drug, which can be obtained by the above production process.

Abstract: Provided is a complex comprising cisplatin encapsulated therein in a form in which a chlorine ion thereof is ligand-exchanged with a carboxyl anion of a block copolymer comprising poly(ethylene glycol)-poly(glutamic acid). This complex can be a medicinal preparation to which a novel dosage form decreased in toxicity can be applied.

Abstract: The present invention provides an electrostatic bonding macromolecular micelle drug carrier comprising a block copolymer having a non-chargeable segment and a chargeable segment, for stably carrying a chargeable drug tending to be easily decomposed in vivo such as protein and DNA.

Abstract: The present invention aims to identify the molecule involved in mechanical allodynia, and to develop and provide a pharmaceutical composition to target this molecule such that the composition is effective in the treatment of mechanical allodynia. The present invention also aims to provide a screening method for compounds for use in such pharmaceutical compositions, a method of determining mechanical allodynia, and a treatment method of mechanical allodynia.

Abstract: Provided are a production process for a polymeric micelle which is stable and has a high drug content and a composition containing such polymeric micelle. Disclosed are a production process for a polymeric micelle, comprising the steps of dissolving a drug and a specific copolymer in a water non-miscible organic solvent to prepare a solution, mixing the resulting solution with water to form an O/W type emulsion and then slowly volatilizing the organic solvent from the solution, and a polymeric micelle composition charged therein with a water-scarcely soluble drug, which can be obtained by the above production process.

Abstract: A complex comprising cisplatin and a poly(ethylene glycol)/poly(glutamic acid) block copolymer, wherein the cisplatin is enclosed in the copolymer through ligand displacement in which a carboxyl anion of the copolymer is replaced with a chlorine ion of the cisplatin. This complex can give a medicine reduced in toxicity and usable by a new method of administration.

Abstract: The present invention provides an electrostatic bonding macromolecular micelle drug carrier comprising a block copolymer having a non-chargeable segment and a chargeable segment, for stably carrying a chargeable drug tending to be easily decomposed in vivo such as protein and DNA.

Abstract: Provided are a production process for a polymeric micelle which is stable and has a high drug content and a composition containing such polymeric micelle. Disclosed are a production process for a polymeric micelle, comprising the steps of dissolving a drug and a specific copolymer in a water non-miscible organic solvent to prepare a solution, mixing the resulting solution with water to form an O/W type emulsion and then slowly volatilizing the organic solvent from the solution, and a polymeric micelle composition charged therein with a water-scarcely soluble drug, which can be obtained by the above production process.

Abstract: The present invention provides an electrostatic bonding type macromolecular micell drug carrier comprising a block copolymer having a non-chargeable segment and a chargeable segment, for stably carrying a chargeable drug tending to be easily decomposedin vivo such as protein and DNA.

Abstract: A dimer, trimer or tetramer of an anthracycline compound which can be obtained by directly, chemically bonding anthracycline compounds having anticancer activities to each other by an alkali treatment. A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core a dimer, trimer or tetramer of anthracycline compound alone or together with other drugs.

Abstract: This invention is a water-soluble high molecular polymerized drug comprising a water-soluble clock copolymer having a hydrophilic segment and a hydrophobic pharmacological-functioning segment to side chain of which a drug is bonded.The hydrophilic first segments of the present invention include polyethylene glycol, polysaccharides, polyacrylamide, and so on.The hydrophobic segments being attached to a drug include polyaspartic acid, polyglutamic acid, polylysine, or derivatives thereof.Drugs to be attached to the hydrophobic segment include anti-cancer drugs, drugs for central nerve, drugs for circulatory organs, and so on.

Abstract: The present invention relates to a bifunctional polyether having groups different from each other at both ends, with a polymerization degree of 5 to 10000 and consisting of repeating units each represented by the following formula (I): ##STR1## (wherein R.sub.1, represents a hydrogen atom, halogen atom, or a lower alkyl group optionally substituted by a halogen atom, and R.sub.1 in each repeating unit may be the same or different), as well as to a process for the preparation thereof and a polymerization initiator therefor. The process of production and polymerization initiator of the present invention enable 100% introduction of a primary amino group into one of the ends of polyether.